146 related articles for article (PubMed ID: 29410961)
21. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI).
Butt Z; Parikh ND; Beaumont JL; Rosenbloom SK; Syrjala KL; Abernethy AP; Benson AB; Cella D
Cancer; 2012 Dec; 118(23):5997-6004. PubMed ID: 22605658
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
[TBL] [Abstract][Full Text] [Related]
24. Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma.
Wang JW; Qian Y; Wu CS; Zhao NH; Fang Y; Yuan XD; Gao S; Fan YC; Wang K
Int J Med Sci; 2020; 17(18):3190-3199. PubMed ID: 33173438
[No Abstract] [Full Text] [Related]
25. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications.
Zhang P; Liu XK; Chu Z; Ye JC; Li KL; Zhuang WL; Yang DJ; Jiang YF
J Int Med Res; 2012; 40(5):1654-61. PubMed ID: 23206447
[TBL] [Abstract][Full Text] [Related]
26. [Clinical characteristics and imaging diagnosis of early cancer in the hepatobiliary and pancreatic region].
Mizumoto R; Ogura Y; Matsuda S
Gan No Rinsho; 1988 Aug; 34(10):1342-8. PubMed ID: 3050200
[TBL] [Abstract][Full Text] [Related]
27. Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma.
Çavuş B; Akyuz F; İliaz R; Akyuz U; Duranyıldız D; Serilmez M; Tekin D; Evirgen S; Karaca Ç; Demir K; Beşışık F; Kaymakoğlu S
Exp Oncol; 2020 Sep; 42(3):208-214. PubMed ID: 32996733
[TBL] [Abstract][Full Text] [Related]
28. Plasma interleukin 17 in the diagnosis of hepatocellular carcinoma: a retrospective study of 39 cases.
Liu J; Zhou G; Lu W
J Cancer Res Ther; 2014 Dec; 10 Suppl():304-6. PubMed ID: 25693940
[TBL] [Abstract][Full Text] [Related]
29. Serological biomarkers of hepatocellular carcinoma in Egyptian patients.
El-Tayeh SF; Hussein TD; El-Houseini ME; Amer MA; El-Sherbini M; Elshemey WM
Dis Markers; 2012; 32(4):255-63. PubMed ID: 22430192
[TBL] [Abstract][Full Text] [Related]
30. The role of a protease inhibitor against hepatectomy.
Gotohda N; Iwagaki H; Ozaki M; Konishi M; Nakagohri T; Takahashi S; Yagi T; Kinoshita T; Tanaka N
Hepatogastroenterology; 2006; 53(67):115-9. PubMed ID: 16506388
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.
Kojima M; Sudo H; Kawauchi J; Takizawa S; Kondou S; Nobumasa H; Ochiai A
PLoS One; 2015; 10(2):e0118220. PubMed ID: 25706130
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the role of interleukin-6 in diagnosis of hepatocellular carcinoma.
El-Folly RF; El-Kabarity RH; Arafa NA
Egypt J Immunol; 2010; 17(2):11-22. PubMed ID: 23082483
[TBL] [Abstract][Full Text] [Related]
34. [Association of serum inflammatory cytokines and Resolvin D1 concentration with pathological stage of colon cancer].
Zhuang Q; Meng Q; Xi Q; Wu G
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1285-1290. PubMed ID: 30506541
[TBL] [Abstract][Full Text] [Related]
35. Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma.
Jekarl DW; Lee S; Kwon JH; Nam SW; Kim M; Kim Y; Jang JW
PLoS One; 2019; 14(11):e0224318. PubMed ID: 31751357
[TBL] [Abstract][Full Text] [Related]
36. Impact of IL-27p28 (rs153109) and TNF-α (rs1800629) Genetic Polymorphisms on the Progression of HCV Infection in Egyptian Patients.
Tharwat E; Gad GFM; Nazmy MH; Mohamed HI; Hamza N; Wahid A; Ibrahim ARN
Immunol Invest; 2019 Apr; 48(3):255-267. PubMed ID: 30204505
[TBL] [Abstract][Full Text] [Related]
37. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
[TBL] [Abstract][Full Text] [Related]
38. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy.
Cha H; Lee EJ; Seong J
World J Gastroenterol; 2017 Mar; 23(11):2077-2085. PubMed ID: 28373775
[TBL] [Abstract][Full Text] [Related]
39. Screening high risk populations for cancer: Hepatobiliary.
Bailey A; Shah SA
J Surg Oncol; 2019 Oct; 120(5):847-850. PubMed ID: 31309559
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological characteristics of multiple primary cancers in hepatobiliary and pancreas malignancies.
Nanashima A; Kondo H; Nakashima M; Abo T; Arai J; Ishii M; Hidaka S; Kunizaki M; To K; Takeshita H; Yamasaki N; Tsuchiya T; Nagayasu T
Anticancer Res; 2015 Feb; 35(2):1073-83. PubMed ID: 25667496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
